Healthcare Industry News: entecavir
News Release - October 30, 2006
Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B PatientsData Also Showed Higher Incidence of Resistance Over Three Years in Lamivudine-Refractory Patients
BOSTON, Oct. 30 (HSMN NewsFeed) -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced three-year results of the BARACLUDEŽ (entecavir) resistance monitoring program, which found the incidence of resistance to be low among patients treated with BARACLUDE in nucleoside-naive studies (n=673). Two patients, or less than one percent, experienced viral rebound due to BARACLUDE resistance through week 144. Study results also indicated a higher incidence of resistance in patients treated with BARACLUDE over three years in lamivudine-refractory studies. Viral rebound due to BARACLUDE resistance occurred in 15 percent (n=13/85) of patients in lamivudine-refractory studies during year three. Lamivudine resistance mutations are required for the development of BARACLUDE resistance. The study results were presented today at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Drug resistance occurs when a virus mutates to avoid the effects of the medication. This can make treatment of hepatitis B challenging because it can decrease the efficacy of the current medication and may compromise future treatment options. "Despite the fact that the hepatitis B virus is constantly changing, BARACLUDE creates a high barrier to resistance development in nucleoside-naive patients, as demonstrated by the less than one percent resistance rate through three years," said Richard Colonno, Ph.D., vice president for virology drug discovery at Bristol-Myers Squibb.
About the analysis
More than 700 patients across six studies initiated therapy on BARACLUDE and were monitored for treatment efficacy, safety and resistance.
The year three analysis evaluated those patients who received treatment with BARACLUDEŽ (entecavir) during the third year (n=152 for patients in nucleoside-naive studies and n=85 for patients in lamivudine-refractory studies). In this comprehensive analysis, all patients enrolled in Bristol- Myers Squibb clinical trials ETV-014, -015, -022, -027, -026 and -901 who experienced a virologic rebound (greater than or equal to one log increase in HBV DNA from nadir by PCR), or whose virus had not yet reached undetectable levels (by definition HBV DNA levels >300 copies/mL as measured by a common assay -- polymerase chain reaction, or PCR) at weeks 48, 96, 144 or end of dosing, as well as patients who discontinued treatment were sequenced to determine if any changes occurred in the genetic code of the virus that would result in resistance or loss of effectiveness of BARACLUDE.
Viral load reduction in chronic hepatitis B patients treated with BARACLUDE in nucleoside-naive and lamivudine-refractory studies was also evaluated.
The incidence of BARACLUDE resistance in patients in nucleoside-naive studies over time is low, with less than one percent of patients experiencing a viral rebound due to BARACLUDE resistance through week 144. BARACLUDE requires at least three different mutations to develop resistance.
-- Viral rebound due to BARACLUDE resistance (rtS202G) occurred in one patient out of 673 treated during the first year, who had lamivudine resistance (rtL180M and rtM204V/I) at the time of study entry and was initiated on 0.5 mg.
-- No additional viral rebounds due to BARACLUDE resistance were observed during the second year of treatment.
-- Viral rebound due to BARACLUDE resistance occurred in one additional patient out of 152 treated during the third year of treatment.
The emergence of resistance increased over three years in patients in lamivudine-refractory studies.
-- Viral rebound due to resistance occurred in one percent (2/192) of patients during the first year of treatment.
-- Viral rebound due to BARACLUDE resistance occurred in an additional nine percent (14/154) of patients during the second year of treatment.
-- Viral rebound due to BARACLUDEŽ (entecavir) resistance occurred in an additional 15 percent (13/85) of patients during the third year.
-- The results in these patients in years one through three were consistent with the finding that the presence of lamivudine-resistant substitutions resulted in an increase in the emergence of BARACLUDE resistance.
Of all BARACLUDE-treated patients with PCR measurements on treatment (intent-to-treat cumulative):
-- 94 percent of patients in nucleoside-naive studies achieved an undetectable viral load (<300 copies/mL) by the end of year three.
-- 40 percent of patients in lamivudine-refractory studies achieved an undetectable viral load (<300 copies/mL) by the end of year three.
Discovered at Bristol-Myers Squibb, BARACLUDE is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication with either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. In addition to the United States, BARACLUDE has been approved in more than 50 countries and regions around the world.
Important Information About BARACLUDE 0.5mg/1mg Tablets
BARACLUDE is a prescription medicine used for chronic infection with hepatitis B virus (HBV) in adults where the virus is multiplying and damaging the liver. BARACLUDE does not cure HBV or stop the spread of HBV to others.
People should not take BARACLUDE if they are allergic to it or any of its ingredients. BARACLUDE has not been studied in children and is not recommended for anyone less than 16 years of age.
People taking BARACLUDE should tell their healthcare provider right away if they feel very weak or tired, have unusual muscle pain, have trouble breathing, have stomach pain with nausea and vomiting, feel cold -- especially in their arms and legs, feel dizzy or lightheaded, or have a fast or irregular heartbeat, as they may be signs of a serious condition called lactic acidosis (buildup of an acid in the blood).
Lactic acidosis is a medical emergency and must be treated in the hospital. Some people who have taken medicines like BARACLUDEŽ (entecavir) have developed serious liver problems called hepatotoxicity. This may occur with liver enlargement (hepatomegaly) and fat in the liver (steatosis).
People should call their healthcare provider right away if they get any of the following signs of liver problems: yellowing (jaundice) of the skin or the white part of the eyes, darkening of the urine, lightening in the color of bowel movements (stools), not feeling like eating food for several days or longer, feeling sick to the stomach (nausea), or having lower stomach pain. Lactic acidosis and hepatotoxicity have happened in some people taking medicines like BARACLUDE.
In some people, hepatitis B symptoms may get worse or become very serious when they stop taking BARACLUDE. People should not stop BARACLUDE without talking to their healthcare provider. Healthcare providers will need to follow their patients and do blood tests to check the liver when BARACLUDE is stopped. People should tell their healthcare provider if they have or develop kidney problems because their healthcare provider may want to do tests to see if a lower dose is needed.
Because BARACLUDE is removed from the body through the kidneys, a lower dose may be required. Healthcare providers may want to perform tests to determine whether a patient needs a lower dose.
It is not known if BARACLUDE is safe to use during pregnancy. It is not known if BARACLUDE helps to prevent a pregnant mother from passing HBV to her baby. A pregnant woman and her healthcare provider will need to decide if BARACLUDE is right for her. A woman should not breastfeed if she is taking BARACLUDE.
People should discuss with their healthcare provider all prescription and non-prescription medicines, vitamins, herbal supplements, and other health preparations they are taking or plan to take. BARACLUDE may interact with medicines that leave the body through the kidneys. The most common side effects of BARACLUDE in clinical studies were headache, tiredness, dizziness, and nausea.
This list of side effects is not complete at this time because BARACLUDE is still under study. People should report any new or continuing symptom to their healthcare provider. BARACLUDE should be taken once daily on an empty stomach (at least two hours after a meal and two hours before the next meal). To learn more about BARACLUDEŽ (entecavir) and for Full Prescribing Information, including boxed WARNINGS, please visit www.bms.com.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
BARACLUDE (entecavir) is a trademark of Bristol-Myers Squibb Company. Full prescribing information for BARACLUDE, including boxed WARNINGS, is available at www.bms.com.
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.